Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review.

Q3 Medicine Innovations in clinical neuroscience Pub Date : 2024-09-01 eCollection Date: 2024-07-01
Waguih William IsHak, Ashley Meyer, Luiza Freire, Jayant Totlani, Nathalie Murphy, Sabrina Renteria, Mohamed Salem, Tiffany Chang, Rasha Abdelsalam, Rida Khan, Thomas Chandy, Thomas Parrish, Drew Hirsch, Bhumika Patel, Alexander J Steiner, Sarah Kim, Rebecca Hedrick, Robert N Pechnick, Itai Danovitch
{"title":"Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review.","authors":"Waguih William IsHak, Ashley Meyer, Luiza Freire, Jayant Totlani, Nathalie Murphy, Sabrina Renteria, Mohamed Salem, Tiffany Chang, Rasha Abdelsalam, Rida Khan, Thomas Chandy, Thomas Parrish, Drew Hirsch, Bhumika Patel, Alexander J Steiner, Sarah Kim, Rebecca Hedrick, Robert N Pechnick, Itai Danovitch","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This systematic review provides an overview of psychiatric medications in the late stages of development (Phase III clinical trials) as of June 1, 2024. It details the mechanisms of action, efficacy, dosing, and adverse effects of these medications.</p><p><strong>Methods: </strong>We searched the PubMed database for Phase III studies of psychiatric medications published until June 1, 2024, using the keywords \"psychiatric\" OR \"psychopharm*\" AND \"medic*\" OR \"pharm*\". Our review encompassed medications currently undergoing Phase III clinical trials and those that have completed Phase III but are awaiting approval from the United States Food and Drug Administration (FDA). We independently analyzed the identified studies and reached a consensus on the medications to be included in this systematic review.</p><p><strong>Results: </strong>As of June 1, 2024, a total of 89 pipeline drug trials were identified, including nine for schizophrenia, five for bipolar disorders, 25 for depressive disorders, 11 for anxiety disorders, five for post-traumatic stress disorder (PTSD), one for obsessive compulsive disorder (OCD), two for eating disorders, two for sleep-wake disorders, three for sexual dysfunctions, one for substance-related and addictive disorders, 22 for neurocognitive disorders, and three for neurodevelopmental disorders, specifically attention deficit hyperactivity disorder (ADHD).</p><p><strong>Conclusion: </strong>The psychiatric medications in the pipeline as of June 1, 2024, demonstrate significant promise in treating psychiatric disorders.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"21 7-9","pages":"27-47"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424068/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innovations in clinical neuroscience","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This systematic review provides an overview of psychiatric medications in the late stages of development (Phase III clinical trials) as of June 1, 2024. It details the mechanisms of action, efficacy, dosing, and adverse effects of these medications.

Methods: We searched the PubMed database for Phase III studies of psychiatric medications published until June 1, 2024, using the keywords "psychiatric" OR "psychopharm*" AND "medic*" OR "pharm*". Our review encompassed medications currently undergoing Phase III clinical trials and those that have completed Phase III but are awaiting approval from the United States Food and Drug Administration (FDA). We independently analyzed the identified studies and reached a consensus on the medications to be included in this systematic review.

Results: As of June 1, 2024, a total of 89 pipeline drug trials were identified, including nine for schizophrenia, five for bipolar disorders, 25 for depressive disorders, 11 for anxiety disorders, five for post-traumatic stress disorder (PTSD), one for obsessive compulsive disorder (OCD), two for eating disorders, two for sleep-wake disorders, three for sexual dysfunctions, one for substance-related and addictive disorders, 22 for neurocognitive disorders, and three for neurodevelopmental disorders, specifically attention deficit hyperactivity disorder (ADHD).

Conclusion: The psychiatric medications in the pipeline as of June 1, 2024, demonstrate significant promise in treating psychiatric disorders.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
截至 2024 年 6 月 1 日正在进行 III 期临床试验的精神科药物概览:系统回顾。
目的:本系统综述概述了截至 2024 年 6 月 1 日处于开发后期(III 期临床试验)的精神科药物。它详细介绍了这些药物的作用机制、疗效、剂量和不良反应:我们使用关键词 "psychiatric "或 "psychopharm*"和 "medic*",在 PubMed 数据库中检索了截至 2024 年 6 月 1 日发表的精神科药物 III 期临床研究。和 "medic*"或 "pharm*"。我们的研究包括目前正在进行 III 期临床试验的药物,以及已经完成 III 期临床试验但正在等待美国食品药品管理局 (FDA) 批准的药物。我们对确定的研究进行了独立分析,并就纳入本系统综述的药物达成了共识:截至 2024 年 6 月 1 日,共确定了 89 项管线药物试验,其中包括 9 项精神分裂症试验、5 项双相情感障碍试验、25 项抑郁障碍试验、11 项焦虑障碍试验、5 项创伤后应激障碍试验、1 项强迫症试验、2 项进食障碍试验、2 项创伤后应激障碍试验、1 项强迫症试验、2 例进食障碍、2 例睡眠-觉醒障碍、3 例性功能障碍、1 例药物相关和成瘾性障碍、22 例神经认知障碍和 3 例神经发育障碍,特别是注意力缺陷多动障碍(ADHD)。结论截至 2024 年 6 月 1 日,正在研发中的精神科药物在治疗精神障碍方面大有可为。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Innovations in clinical neuroscience
Innovations in clinical neuroscience Medicine-Psychiatry and Mental Health
CiteScore
2.10
自引率
0.00%
发文量
87
期刊最新文献
Activation of the serotonergic neurotransmission is a double-edged sword in the treatment of burning mouth syndrome. Literary Prescriptions: Applying Bibliotherapy in a Psychotherapeutic Context. Neuropsychological Functioning Among Patients with OCD in Asian Countries: A Systematic Review. Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review. Risk Management: Fires, Floods, Hurricanes, Oh My! The Importance of Disaster Planning.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1